Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Average Rating of “Reduce” by Analysts

Kezar Life Sciences, Inc. (NASDAQ:KZR) has earned an average recommendation of “Reduce” from the six brokerages that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating and four have assigned a hold rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $6.00.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Kezar Life Sciences in a research report on Friday.

Kezar Life Sciences Trading Down 1.0%

KZR stock opened at $7.29 on Tuesday. The firm has a 50 day moving average of $7.12 and a 200-day moving average of $6.56. Kezar Life Sciences has a 12-month low of $3.53 and a 12-month high of $7.55. The company has a market cap of $53.87 million, a price-to-earnings ratio of -0.95 and a beta of 0.40.

Kezar Life Sciences (NASDAQ:KZR) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.20. Sell-side analysts forecast that Kezar Life Sciences will post -3.58 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in Kezar Life Sciences by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 68,167 shares of the company’s stock valued at $429,000 after acquiring an additional 2,665 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Kezar Life Sciences by 14.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 26,543 shares of the company’s stock valued at $167,000 after acquiring an additional 3,312 shares during the last quarter. State Street Corp raised its holdings in Kezar Life Sciences by 28.4% in the 4th quarter. State Street Corp now owns 27,093 shares of the company’s stock valued at $170,000 after acquiring an additional 6,000 shares during the last quarter. Bridgeway Capital Management LLC raised its holdings in Kezar Life Sciences by 25.9% in the 4th quarter. Bridgeway Capital Management LLC now owns 51,638 shares of the company’s stock valued at $325,000 after acquiring an additional 10,638 shares during the last quarter. Finally, Peapod Lane Capital LLC raised its holdings in Kezar Life Sciences by 9.3% in the 3rd quarter. Peapod Lane Capital LLC now owns 125,773 shares of the company’s stock valued at $491,000 after acquiring an additional 10,650 shares during the last quarter. 67.90% of the stock is currently owned by institutional investors and hedge funds.

Kezar Life Sciences Company Profile

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.